You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

66 search results for: mechanism of disease

The Impact <b>of</b> Skin Fibrosis in Patients with Prurigo Nodularis
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

Dermatology
An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.
View more
A brief overview <b>of</b> the pathophysiology <b>of</b> PN
expert video

A brief overview of the pathophysiology of PN

Dermatology
Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.
View more
Diagnostic Considerations: Coexistence, and Distinctions <b>of</b> AD & PN
expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

Dermatology
Dr. Mark Tang talks about the coexistence of AD and PN and considerations for choosing treatment.
View more
Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Dermatology
Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.
View more
The Evolving Understanding <b>of</b> Prurigo Nodularis (PN) Has Implications for Patient Management
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Dermatology
An infographic summarizing the clinical manifestations and pathophysiological processes of PN.
View more
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
View more
Type 2 Inflammation Alters the Structure and Function <b>of</b> the Skin in AD
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

Dermatology
Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.
View more
Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis
expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

Dermatology
Dr. Stephan Weidinger explains how type 2 cytokines impact the skin microbiome in AD.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
The Impact <b>of</b> Skin Dysbiosis on Atopic Dermatitis
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

Dermatology
Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.
View more
The Impact <b>of</b> Type 2 Inflammation on the Neuroimmune Axis in AD
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

Dermatology
Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis– Presentation from the ADVENT symposium at EAACI 2023.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region